All In Biotech

NDA 021287 · Advanz Pharma

Uroxatral

Alfuzosin Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: May 22, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jun 12, 2003

Approved uses

2

Original approval plus efficacy supplements

Registered trials

46

18 Phase 3, 0 recruiting

FAERS reports

3,374

1,950 serious, 242 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 5, 2024.

UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. ( 1 ) Important Limitations of Use: UROXATRAL is not indicated for treatment of hypertension. ( 1.1 ) UROXATRAL is not indicated for use in the pediatric population. ( 1.1 , 8.4 , 12.3 ) 1.1 Important Limitations of Use UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population.

Mechanism: Alfuzosin is a selective antagonist of post-synaptic alpha 1 -adrenoreceptors, which are located in the prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • UROXATRAL · ALFUZOSIN HYDROCHLORIDE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Alfuzosin" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness252
  • drug ineffective206
  • fatigue200
  • dyspnoea145
  • asthenia132
  • nausea132
  • fall126
  • diarrhoea124
  • headache119
  • hypotension102
  • syncope97
  • insomnia94

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004279
2005270
2006180
2007129
2008140
2009183
2010301
2011312
2012275
2013103
201487
2015177
2016196
2017163
2018127
2019102
2020117
202195
202230
202323
202431
202532
202622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Uroxatral (Alfuzosin HCl)

2024 spending

$1.7M

Beneficiaries

231

1,045 claims

Per beneficiary

$7,446

$25.58 per unit

View as table
YearSpending
2020$2,045,196
2021$1,881,630
2022$1,917,293
2023$1,932,243
2024$1,720,101

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 156 on PubMed

Sponsor: Advanz Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.